PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
NGNE vs. WSM
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between NGNE and WSM is 0.17, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

NGNE vs. WSM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Neurogene Inc (NGNE) and Williams-Sonoma, Inc. (WSM). The values are adjusted to include any dividend payments, if applicable.

-50.00%0.00%50.00%100.00%SeptemberOctoberNovemberDecember2025February
-50.34%
40.87%
NGNE
WSM

Key characteristics

Sharpe Ratio

NGNE:

-0.35

WSM:

1.49

Sortino Ratio

NGNE:

0.24

WSM:

2.35

Omega Ratio

NGNE:

1.04

WSM:

1.31

Calmar Ratio

NGNE:

-0.43

WSM:

3.69

Martin Ratio

NGNE:

-0.99

WSM:

8.12

Ulcer Index

NGNE:

42.02%

WSM:

9.49%

Daily Std Dev

NGNE:

117.98%

WSM:

51.86%

Max Drawdown

NGNE:

-98.18%

WSM:

-89.01%

Current Drawdown

NGNE:

-96.08%

WSM:

-10.35%

Fundamentals

Market Cap

NGNE:

$593.14M

WSM:

$24.03B

EPS

NGNE:

-$3.66

WSM:

$8.45

Total Revenue (TTM)

NGNE:

$925.00K

WSM:

$5.25B

Gross Profit (TTM)

NGNE:

-$15.64M

WSM:

$2.47B

EBITDA (TTM)

NGNE:

-$53.17M

WSM:

$1.05B

Returns By Period

In the year-to-date period, NGNE achieves a -24.06% return, which is significantly lower than WSM's 5.70% return. Over the past 10 years, NGNE has underperformed WSM with an annualized return of -21.83%, while WSM has yielded a comparatively higher 19.94% annualized return.


NGNE

YTD

-24.06%

1M

8.84%

6M

-50.31%

1Y

-42.69%

5Y*

-39.06%

10Y*

-21.83%

WSM

YTD

5.70%

1M

-7.98%

6M

40.87%

1Y

75.68%

5Y*

42.61%

10Y*

19.94%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

NGNE vs. WSM — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NGNE
The Risk-Adjusted Performance Rank of NGNE is 3030
Overall Rank
The Sharpe Ratio Rank of NGNE is 2828
Sharpe Ratio Rank
The Sortino Ratio Rank of NGNE is 3939
Sortino Ratio Rank
The Omega Ratio Rank of NGNE is 4040
Omega Ratio Rank
The Calmar Ratio Rank of NGNE is 2121
Calmar Ratio Rank
The Martin Ratio Rank of NGNE is 2323
Martin Ratio Rank

WSM
The Risk-Adjusted Performance Rank of WSM is 8989
Overall Rank
The Sharpe Ratio Rank of WSM is 8787
Sharpe Ratio Rank
The Sortino Ratio Rank of WSM is 8585
Sortino Ratio Rank
The Omega Ratio Rank of WSM is 8484
Omega Ratio Rank
The Calmar Ratio Rank of WSM is 9696
Calmar Ratio Rank
The Martin Ratio Rank of WSM is 8989
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

NGNE vs. WSM - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Neurogene Inc (NGNE) and Williams-Sonoma, Inc. (WSM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for NGNE, currently valued at -0.35, compared to the broader market-2.000.002.00-0.351.49
The chart of Sortino ratio for NGNE, currently valued at 0.24, compared to the broader market-4.00-2.000.002.004.006.000.242.35
The chart of Omega ratio for NGNE, currently valued at 1.04, compared to the broader market0.501.001.502.001.041.31
The chart of Calmar ratio for NGNE, currently valued at -0.43, compared to the broader market0.002.004.006.00-0.433.69
The chart of Martin ratio for NGNE, currently valued at -0.99, compared to the broader market-10.000.0010.0020.0030.00-0.998.12
NGNE
WSM

The current NGNE Sharpe Ratio is -0.35, which is lower than the WSM Sharpe Ratio of 1.49. The chart below compares the historical Sharpe Ratios of NGNE and WSM, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.001.002.003.004.005.00SeptemberOctoberNovemberDecember2025February
-0.35
1.49
NGNE
WSM

Dividends

NGNE vs. WSM - Dividend Comparison

NGNE has not paid dividends to shareholders, while WSM's dividend yield for the trailing twelve months is around 1.17%.


TTM20242023202220212020201920182017201620152014
NGNE
Neurogene Inc
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
WSM
Williams-Sonoma, Inc.
1.17%1.16%1.72%2.65%1.43%1.93%2.55%3.33%2.98%3.02%2.36%1.72%

Drawdowns

NGNE vs. WSM - Drawdown Comparison

The maximum NGNE drawdown since its inception was -98.18%, which is greater than WSM's maximum drawdown of -89.01%. Use the drawdown chart below to compare losses from any high point for NGNE and WSM. For additional features, visit the drawdowns tool.


-100.00%-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-96.08%
-10.35%
NGNE
WSM

Volatility

NGNE vs. WSM - Volatility Comparison

Neurogene Inc (NGNE) has a higher volatility of 29.28% compared to Williams-Sonoma, Inc. (WSM) at 10.58%. This indicates that NGNE's price experiences larger fluctuations and is considered to be riskier than WSM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


0.00%20.00%40.00%60.00%80.00%100.00%SeptemberOctoberNovemberDecember2025February
29.28%
10.58%
NGNE
WSM

Financials

NGNE vs. WSM - Financials Comparison

This section allows you to compare key financial metrics between Neurogene Inc and Williams-Sonoma, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab